A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers

作者：El Rayes B F^*; Zalupski M; Bekai Saab T; Heilbrun L K; Hammad N; Patel B; Urba S; Shields A F; Vaishampayan U; Dawson S; Almhanna K; Smith D; Philip P A

来源：Annals of Oncology, 2010, 21(10): 1999-2004.

DOI：10.1093/annonc/mdq065

• bevacizumab
• docetaxel
• gastric cancer
• oxaliplatin

Patients and methods: Previously untreated patients with locally advanced or metastatic disease and a performance status (PS) of 0-1 were eligible for this study. Patients received bevacizumab at 7.5 mg/kg, docetaxel at 70 mg/m(2), and oxaliplatin at 75 mg/m(2) administered on day 1 of a 21-day cycle. The primary end point of the study was progression-free survival (PFS).
Results: A total of 38 eligible patients (median age 57 years, 45% gastric, 55% PS 0) were enrolled on to the study. Median PFS was 6.6 months [95% confidence interval (CI) 4.4-10.5] and median survival 11.1 months (95% CI 8.2-15.3). Complete responses were documented in 2 (5%) patients, partial responses in 14 (37%), and stable disease in 14 (37%). No treatment-related deaths were observed. The most commonly reported grade 3-4 toxicity was neutropenia (34%), and gastrointestinal perforation occurred in three patients (8%).
Conclusion: The combination of bevacizumab, docetaxel, and oxaliplatin has promising activity for further evaluation in randomized trials.

• 出版日期2010-10